Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.74 |
| ▸ | CNR2 | P34972 | 13/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312748 | 0.92 | CNR1 (0.88) | CNR1CNR2KCNH2 | |
| SCHEMBL3310852 | 0.87 | CNR1 (0.67) | CNR1CNR2KCNH2 | |
| SCHEMBL13329248 | 0.87 | CNR1 (0.78) | CNR1CNR2KCNH2 | |
| SCHEMBL3312351 | 0.83 | CNR1 (1.00) | CNR1CNR2KCNH2 | |
| SCHEMBL3313152 | 0.83 | CNR1 (0.96) | CNR1CNR2KCNH2 | |
| SCHEMBL3315579 | 0.82 | CNR1 (0.75) | CNR1CNR2KCNH2 | |
| SCHEMBL3312765 | 0.82 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3312407 | 0.81 | CNR1 (0.74) | CNR1CNR2KCNH2 | |
| SCHEMBL3313153 | 0.81 | CNR1 (0.69) | CNR1CNR2KCNH2 | |
| SCHEMBL3310915 | 0.80 | CNR1 (0.68) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | claimed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| EP-1863810-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006101434-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885KCNH2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.